LY 3039478

Drug Profile

LY 3039478

Alternative Names: LY3039478

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Lymphoma
  • Phase I Solid tumours

Most Recent Events

  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Cancers (solid tumours and lymphoma) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 01 Nov 2016 Eli Lilly completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02917733)
  • 01 Oct 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, France (PO) (NCT02784795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top